GlassScriptPhysician profile
Terry Joe Declue
NPI 1962481127
$6,406.28
in general payments reported to CMS, 2019-2025
37 companies · $1,879 in 2025
The $1,879 reported for 2025 was more than what 76% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $68.06 · 2021: $552 · 2022: $859 · 2023: $1,298 · 2024: $1,564 · 2025: $1,879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,741.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,740.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $728.58 | 2022-2025 | Skytrofa |
| Abbvie INC. | $503.82 | 2019-2025 | Lupron Depot |
| Dexcom, INC. | $502.67 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $413.52 | 2023-2025 | Sogroya, Wegovy |
| Neurocrine Biosciences, INC. | $403.32 | 2024-2025 | Ingrezza |
| Insulet Corporation | $366.45 | 2021-2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $338.18 | 2023-2025 | |
| Eton Pharmaceuticals, INC. | $281.48 | 2023-2025 | Alkindi, Khindivi, Increlex |
| Tolmar Pharmaceuticals, INC. | $242.32 | 2021-2022 | |
| Abbott Laboratories | $223.50 | 2021-2025 | Freestyle Libre 2 |
| Pfizer INC. | $222.81 | 2019-2025 | |
| Azurity Pharmaceuticals, INC. | $192.30 | 2023-2025 | Triptodur, Triptodur |
| Beta Bionics, INC. | $188.73 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $188.05 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $179.09 | 2021-2025 | Gvoke Hypopen |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $152.75 | 2021-2023 | |
| Biomarin Pharmaceutical INC. | $140.19 | 2019-2024 | Palynziq, Voxzogo 1.2mg |
| Medtronic, INC. | $126.05 | 2021-2023 | Minimed 780g |
| Tolmar, INC. | $123.63 | 2023-2025 | Fensolvi |
| Endo USA, INC. | $110.87 | 2024-2025 | Supprelin |
| Sequel Med Tech, LLC | $102.13 | 2025 | Twiist |
| Genzyme Corporation | $96.24 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $93.15 | 2023-2024 | Vpriv |
| Endo Pharmaceuticals INC. | $84.23 | 2020-2023 | Supprelin |
| Kyowa Kirin, INC. | $63.22 | 2023-2025 | Crysvita |
| Zealand Pharma US, INC. | $62.55 | 2021-2022 | |
| Embecta Corp. | $42.45 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Rhythm Pharmaceuticals, INC. | $41.83 | 2022-2023 | Imcivree |
| Lilly USA, LLC | $33.33 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $24.67 | 2023 | Crysvita |
| Ibsa Pharma INC. | $24.33 | 2024 | Licart, Tirosint |
| Chiesi USA, INC. | $23.45 | 2024 | Myalept |
| Soleno Therapeutics, INC. | $19.03 | 2025 | Vykat Xr |
| Eusa Pharma (US) LLC | $18.45 | 2022 | |
| Recordati_rare_diseases_inc. | $18.45 | 2022 | |
| Becton, Dickinson and Company | $17.76 | 2022 | |
| Ptc Therapeutics, INC. | $12.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Declue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.